Heparin-induced thrombocytopenia and the clinical use of low molecular weight heparins in acute coronary syndromes.
Standard unfractionated heparin has long been the mainstay of anticoagulant therapy. Despite its significant therapeutic benefits, unfractionated heparin has disadvantages in clinical usage, including the need for continuous intravenous infusion or multiple daily injections, and close laboratory monitoring of the activated partial thromboplastin time (aPTT) and/or plasma heparin concentrations, as well as risk for bleeding complications and heparin-induced thrombocytopenia (HIT). Low-molecular-weight (LMW) heparins have shown equivalent efficacy or superiority to unfractionated heparin, while permitting easier dosage and administration, and posing less risk for bleeding complications and HIT. A review of the clinical use of LMW heparins in acute coronary syndromes reveals a low incidence of HIT. However, LMW heparins are not recommended for the treatment of established HIT due to cross-reaction with 80% of antibodies generated during exposure to unfractionated heparin.